CLAIM AMENDMENTS

1 (Original). A pharmaceutical composition useful in treating heart transplant rejection in mammals, which composition comprises one or more pharmaceutically acceptable excipients, a therapeutically effective amount of a non-peptide CCR1 receptor antagonist and a sub-nephrotoxic amount of cyclosporin A.

2 (Original). The pharmaceutical composition of Claim 1 wherein the non-peptide CCR1 receptor antagonist is a compound selected from formula (I):



(I)

wherein:

R^{1a} is one or more substituents independently selected from the group consisting of alkyl or hydroxyalkyl;

R^2 is fluoro at the 4-position;

R^3 is phenyl substituted at the 4-position with chloro and at the 2-position by aminocarbonyl, ureido or glycinamido;

R^4 is -O-;

R^5 is methylene; and

R^6 is -C(O)-;

as a single stereoisomer or a mixture thereof; or a pharmaceutically acceptable salt thereof.

3 (Original). The pharmaceutical composition of Claim 2 wherein the non-peptide CCR1 receptor antagonist is selected from the group consisting of:

(2*R*,5*S*)-1-((4-chloro-2-(aminocarbonyl)phenoxy)methyl)carbonyl-2,5-dimethyl-4-(4-fluorobenzyl)piperazine;

(*trans*)-1-((4-chloro-2-(glycinamido)phenoxy)methyl)carbonyl-2,5-dimethyl-4-(4-fluorobenzyl)piperazine;

(2*R*)-1-((4-chloro-2-(ureido)phenoxy)methyl)carbonyl-2-methyl-4-(4-fluorobenzyl)piperazine;

(*trans*)-1-((4-chloro-2-(ureido)phenoxy)methyl)carbonyl-2,5-dimethyl-4-(4-fluorobenzyl)piperazine;

(2*R*,5*S*)-1-((4-chloro-2-(ureido)phenoxy)methyl)carbonyl-2,5-dimethyl-4-(4-fluorobenzyl)piperazine; and

(2*R*,5*S*)-1-((4-chloro-2-(glycinamido)phenoxy)methyl)carbonyl-2,5-dimethyl-4-(4-fluorobenzyl)piperazine.

4 (Original). The pharmaceutical composition of Claim 2 wherein the non-peptide CCR1 receptor antagonist is (2*R*)-1-((4-chloro-2-(ureido)phenoxy)methyl)carbonyl-2-methyl-4-(4-fluorobenzyl)piperazine.

5 (Original). The pharmaceutical composition of Claim 4 wherein the mammal in need thereof is a human.

6 (Currently Amended). A method of administering to a mammal in need thereof a pharmaceutical composition useful in treating heart transplant rejection in mammals, wherein said method comprises administering said pharmaceutical composition to a mammal, which pharmaceutical composition comprises a one or more pharmaceutically acceptable excipients, a therapeutically effective amount of a non-peptide CCR1 receptor antagonist and a sub-nephrotoxic amount of cyclosporin A.

7 (Original). The method of Claim 6 wherein the non-peptide CCR1 receptor antagonist and the cyclosporin A are administered to the mammal in need thereof simultaneously or sequentially.

8 (Original). The method of Claim 7 wherein the non-peptide CCR1 receptor antagonist is a compound selected from formula (I):



(I)

wherein:

R^{1a} is one or more substituents independently selected from the group consisting of alkyl or hydroxyalkyl;

R^2 is fluoro at the 4-position;

R^3 is phenyl substituted at the 4-position with chloro and at the 2-position by aminocarbonyl, ureido or glycinamido;

R^4 is -O-;

R^5 is methylene; and

R^6 is -C(O)-;
as a single stereoisomer or a mixture thereof; or a pharmaceutically acceptable salt thereof.

9 (Original). The method of Claim 8 wherein the non-peptide CCR1 receptor antagonist is selected from the group consisting of:
(2*R*,5*S*)-1-((4-chloro-2-(aminocarbonyl)phenoxy)methyl)carbonyl-2,5-dimethyl-4-(4-fluorobenzyl)piperazine;
(*trans*)-1-((4-chloro-2-(glycinamido)phenoxy)methyl)carbonyl-2,5-dimethyl-4-(4-fluorobenzyl)piperazine;
(2*R*)-1-((4-chloro-2-(ureido)phenoxy)methyl)carbonyl-2-methyl-4-(4-fluorobenzyl)piperazine;
(*trans*)-1-((4-chloro-2-(ureido)phenoxy)methyl)carbonyl-2,5-dimethyl-4-(4-fluorobenzyl)piperazine;
(2*R*,5*S*)-1-((4-chloro-2-(ureido)phenoxy)methyl)carbonyl-2,5-dimethyl-4-(4-fluorobenzyl)piperazine; and
(2*R*,5*S*)-1-((4-chloro-2-(glycinamido)phenoxy)methyl)carbonyl-2,5-dimethyl-4-(4-fluorobenzyl)piperazine.

10 (Original). The method of Claim 8 wherein the non-peptide CCR1 receptor antagonist is (2*R*)-1-((4-chloro-2-(ureido)phenoxy)methyl)carbonyl-2-methyl-4-(4-fluorobenzyl)piperazine.

11 (Original). The method of Claim 8 wherein the mammal in need thereof is a human.

12 (Currently Amended). A method of treating heart transplant rejection in a mammal, wherein said ~~which~~ method comprises administering to a mammal in need thereof a pharmaceutical composition, said pharmaceutical composition comprising one or more pharmaceutically acceptable excipients, a therapeutically effective amount of a non-peptide CCR1 receptor antagonist and a sub-nephrotoxic amount of cyclosporin A.

13 (Original). The method of Claim 12 wherein the non-peptide CCR1 receptor antagonist is a compound selected from formula (I):



(I)

n-0500

wherein:

R^{1a} is one or more substituents independently selected from the group consisting of alkyl or hydroxyalkyl;

R^2 is fluoro at the 4-position;

R^3 is phenyl substituted at the 4-position with chloro and at the 2-position by aminocarbonyl, ureido or glycinamido;

R^4 is -O-;

R^5 is methylene; and

R^6 is -C(O)-;

as a single stereoisomer or a mixture thereof; or a pharmaceutically acceptable salt thereof.

14 (Original). The method of Claim 13 wherein the non-peptide CCR1 receptor antagonist is selected from the group consisting of:

(2*R*,5*S*)-1-((4-chloro-2-(aminocarbonyl)phenoxy)methyl)carbonyl-2,5-dimethyl-4-(4-fluorobenzyl)piperazine;

(*trans*)-1-((4-chloro-2-(glycinamido)phenoxy)methyl)carbonyl-2,5-dimethyl-4-(4-fluorobenzyl)piperazine;

(2*R*)-1-((4-chloro-2-(ureido)phenoxy)methyl)carbonyl-2-methyl-4-(4-fluorobenzyl)piperazine;

(*trans*)-1-((4-chloro-2-(ureido)phenoxy)methyl)carbonyl-2,5-dimethyl-4-(4-fluorobenzyl)piperazine;

(2*R*,5*S*)-1-((4-chloro-2-(ureido)phenoxy)methyl)carbonyl-2,5-dimethyl-4-(4-fluorobenzyl)piperazine; and

(2*R*,5*S*)-1-((4-chloro-2-(glycinamido)phenoxy)methyl)carbonyl-2,5-dimethyl-4-(4-fluorobenzyl)piperazine.

15 (Original). The method of Claim 13 wherein the non-peptide CCR1 receptor antagonist is (2*R*)-1-((4-chloro-2-(ureido)phenoxy)methyl)carbonyl-2-methyl-4-(4-fluorobenzyl)piperazine.

16 (Original). The method of Claim 15 wherein the mammal in need thereof is a human.

17 (Original). The method of Claim 15 wherein the non-peptide CCR1 receptor antagonist and the cyclosporin A are administered to the mammal in need thereof simultaneously or sequentially.

n-0500